Similar articles

Abstract: acute cellular rejection (ACR) remains a major concern after liver transplantation. Predicting and monitoring acute rejection by non-invasive methods are very important for guiding the use of immunosuppressive drugs. Many studies have shown that exosomes and their contents are potential biomarkers for various liver diseases. Here, we identify and validate the role of exosomes and galectin-9 in ACR after liver transplantation. exosomes were isolated from three sets of paired patients, with and without ACR, and the proteins within the exosomes were isolated and identified. Candidate proteins were then validated using a tissue microarray containing resected liver samples from 73 ACR and 63 non-rejection patients. Finally, protein expression and clinical manifestations were included in Kaplan-Meier survival and Cox regression analyses. Circulating exosomes were isolated from ACR and non-rejection patients and characterized using transmission electron microscopy and western blotting for CD63/CD81. Western blotting experiments revealed higher levels of galectin-9 protein in circulating exosomes from ACR recipients. Immunohistochemical analysis of the tissue microarray showed that the expression of galectin-9 in resected liver was significantly higher in the ACR group than in the non-rejection group (P<0.05). Higher levels of galectin-9 expression in resected livers were associated with poorer prognosis (P<0.05). exosome-derived galectin-9 may be a novel predictor of rejection and prognosis after liver transplantation.

外泌体来源的半乳糖凝集素-9预测肝移植术后排斥发生及预后

[1]Ashokkumar C, Soltys K, Mazariegos G, et al., 2017. Predicting cellular rejection with a cell-based assay: preclinical evaluation in children. Transplantation, 101(1):131-140.

[2]Boix F, Millan O, san Segundo D, et al., 2016. High expression of CD38, CD69, CD95 and CD154 biomarkers in cultured peripheral T lymphocytes correlates with an increased risk of acute rejection in liver allograft recipients. Immunobiology, 221(5):595-603.

[3]Chagan-Yasutan H, Shiratori B, Siddiqi UR, et al., 2010. The increase of plasma galectin-9 in a patient with insulin allergy: a case report. Clin Mol Allergy, 8:12.

[4]Chen DJ, Peng WH, Jiang H, et al., 2017. Noninvasive detection of acute renal allograft rejection by measurement of soluble Tim-3 in urine. Mol Med Rep, 16(1):915-921.

[5]Dardalhon V, Anderson AC, Karman J, et al., 2010. Tim-3/ galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b⁺Ly-6G⁺ myeloid cells. J Immunol, 185(3):1383-1392.

[6]Demetris AJ, Bellamy C, Hübscher SG, et al., 2016. 2016 comprehensive update of the Banff Working Group on Liver Allograft Pathology: introduction of antibody-mediated rejection. Am J Transplant, 16(10):2816-2835.

[7]Dieudé M, Bell C, Turgeon J, et al., 2015. The 20S proteasome core, active within apoptotic exosome-like vesicles, induces autoantibody production and accelerates rejection. Sci Transl Med, 7(318):318ra200.

[8]Gupta S, Thornley TB, Gao WD, et al., 2012. Allograft rejection is restrained by short-lived TIM-3⁺PD-1⁺Foxp3⁺ Tregs. J Clin Invest, 122(7):2395-2404.

[9]Huang HT, Lu YF, Zhou T, et al., 2018. Innate immune cells in immune tolerance after liver transplantation. Front Immunol, 9:2401.

[10]Kerr N, García-Contreras M, Abbassi S, et al., 2018. Inflammasome proteins in serum and serum-derived extracellular vesicles as biomarkers of stroke. Front Mol Neurosci, 11:309.

[11]Kim N, Yoon YI, Yoo HJ, et al., 2016. Combined detection of serum IL-10, IL-17, and CXCL10 predicts acute rejection following adult liver transplantation. Mol Cells, 39(8):639-644.

[12]https://doi.org/10.14348/molcells.2016.0130

[13]Kurose Y, Wada J, Kanzaki M, et al., 2013. Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney disease. BMC Nephrol, 14:23.

[14]Lazar E, Benedek T, Korodi S, et al., 2018. Stem cell-derived exosomes—an emerging tool for myocardial regeneration. World J Stem Cells, 10(8):106-115.

[15]Lee EC, Kim SH, Park SJ, 2017. Outcomes after liver transplantation in accordance with ABO compatibility: a systematic review and meta-analysis. World J Gastroenterol, 23(35):6516-6533.

[16]Li YM, Shi YY, Li Y, et al., 2018. Soluble Tim-3 and Gal-9 are associated with renal allograft dysfunction in kidney transplant recipients: a cross-sectional study. Int Immunopharmacol, 55:330-335.

[17]Lim JH, Lee CH, Kim KY, et al., 2018. Novel urinary exosomal biomarkers of acute T cell-mediated rejection in kidney transplant recipients: a cross-sectional study. PLoS ONE, 13(9):e0204204.

[18]Meszaros M, Ursic-Bedoya J, Faure S, et al., 2019. Immuno-suppression minimization trials in liver transplantation: can we predict humoral response to assess eligibility? Hepatology, 69(5):2302-2303.

[19]Mousavi S, Moallem R, Hassanian SM, et al., 2019. Tumor-derived exosomes: potential biomarkers and therapeutic target in the treatment of colorectal cancer. J Cell Physiol, 234(8):12422-12432.

[20]Naderi-Meshkin H, Lai X, Amirkhah R, et al., 2019. Exosomal lncRNAs and cancer: connecting the missing links. Bioinformatics, 35(2):352-360.

[21]Naka EL, Ponciano VC, Cenedeze MA, et al., 2009. Detection of the Tim-3 ligand, galectin-9, inside the allograft during a rejection episode. Int Immunopharmacol, 9(6):658-662.

[22]Pike R, Thomas N, Workman S, et al., 2016. PD1-expressing T cell subsets modify the rejection risk in renal transplant patients. Front Immunol, 7:126.

[23]Qiao XW, Jiang K, Nie J, et al., 2014. Increased expression of Tim-3 and its ligand galectin-9 in rat allografts during acute rejection episodes. Biochem Biophys Res Commun, 445(3):542-548.

[24]Raschzok N, Reutzel-Selke A, Schmuck RB, et al., 2015. CD44 and CXCL9 serum protein levels predict the risk of clinically significant allograft rejection after liver transplantation. Liver Transpl, 21(9):1195-1207.

[25]Saitoh H, Ashino Y, Chagan-Yasutan H, et al., 2012. Rapid decrease of plasma galectin-9 levels in patients with acute HIV infection after therapy. Tohoku J Exp Med, 228(2):157-161.

[26]Sakuishi K, Jayaraman P, Behar SM, et al., 2011. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol, 32(8):345-349.

[27]Schlegel A, Linecker M, Kron P, et al., 2017. Risk assessment in high- and low-meld liver transplantation. Am J Transplant, 17(4):1050-1063.

[28]Shen T, Lin BY, Jia JJ, et al., 2014. A modified protocol with rituximab and intravenous immunoglobulin in emergent ABO-incompatible liver transplantation for acute liver failure. Hepatobiliary Pancreat Dis Int, 13(4):395-401.

[29]Sood S, Haifer C, Yu LJ, et al., 2017. A novel immune function biomarker identifies patients at risk of clinical events early following liver transplantation. Liver Transpl, 23(4):487-497.

[30]Su EW, Bi SG, Kane LP, 2011. Galectin-9 regulates T helper cell function independently of Tim-3. Glycobiology, 21(10):1258-1265.

[31]Tang ZH, Liang SW, Potter J, et al., 2013. Tim-3/galectin-9 regulate the homeostasis of hepatic NKT cells in a murine model of nonalcoholic fatty liver disease. J Immunol, 190(4):1788-1796.

[32]Vallabhajosyula P, Korutla L, Habertheuer A, et al., 2017. Tissue-specific exosome biomarkers for noninvasively monitoring immunologic rejection of transplanted tissue. J Clin Invest, 127(4):1375-1391.

[33]van den Hoogen LL, van Roon JAG, Mertens JS, et al., 2018. Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis, 77(12):1810-1814.

[34]Vitalone MJ, Wei L, Fujiki M, et al., 2016. Liver microRNA profile of induced allograft tolerance. Transplantation, 100(4):781-790.

[35]Wang Y, Zhang M, Liu ZW, et al., 2014. The ratio of circulating regulatory T cells (Tregs)/Th17 cells is associated with acute allograft rejection in liver transplantation. PLoS ONE, 9(11):e112135.

[36]Zhou YX, Yang XJ, Zhang H, et al., 2015. The roles of T helper type 17/regulatory T cells in acute rejection after liver transplantation in rats. Transplantation, 99(6):1126-1131.